ERAS-601

DRUG5 trials

Sponsors

Erasca, Inc., Memorial Sloan Kettering Cancer Center

Conditions

Acute Myeloid LeukemiaAdvanced Non-squamous Non-small-cell Lung CancerAdvanced or Metastatic Solid TumorsChordoma

Phase 1

A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors

CompletedNCT04670679

Erasca, Inc.Advanced or Metastatic Solid Tumors

Start: 2020-12-15End: 2026-06-01Updated: 2026-09-16

A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors

CompletedNCT04866134

Erasca, Inc.Advanced or Metastatic Solid Tumors

Start: 2021-05-07End: 2026-07-01Updated: 2026-09-16

A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC

CompletedNCT04959981

Erasca, Inc.Advanced Non-squamous Non-small-cell Lung Cancer

Start: 2021-09-02End: 2023-04-27Updated: 2023-07-25

A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies

WithdrawnNCT05279859

Erasca, Inc.Acute Myeloid Leukemia

Start: 2022-03-15End: 2025-06-01Updated: 2022-06-15

A Study of ERAS-601 in People With Chordoma

Active, not recruitingNCT06957327

Memorial Sloan Kettering Cancer CenterChordoma

Start: 2025-04-25End: 2027-04-01Updated: 2026-04-28

Related Papers

Preliminary results from FLAGSHP-1: A phase 1 study of ERAS-601 as a monotherapy or in combination with cetuximab in patients (pts) previously treated for advanced chordoma.

Journal of Clinical Oncology2024-06-01

Abstract 2670: ERAS-601, a potent allosteric inhibitor of SHP2, synergistically enhances the efficacy of sotorasib/adagrasib and cetuximab in NSCLC, CRC, and HNSCC tumor models

Cancer Research2022-06-153 citations

Abstract 2671: ERAS-601, a potent allosteric inhibitor of SHP2, demonstrates anti-tumor activity in RAS/MAPK-driven tumor models

Cancer Research2022-06-151 citations